anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Arm 1 (n=106) receives the study drug Areplivir for parenteral administration as follows: Day 1 1600 mg 2 times a day, Day 2-10 800 mg 2 times a day. Administration will be done intravenously by drip infusion for 2 hours. The course of treatment is 10 days. The test drug is administered in hospital setting under supervision of a clinical investigator. The test drug is not handed over to the patient.
The present invention provides an externally pasted traditional Chinese medicine plaster mainly for treating bone tuberculosis, and preparation technology for the plaster. The plaster is formed by decocting yellow lead which is added to forty-eight kinds of traditional Chinese medicine which is soaked by benne oil and is fried and deslagged. Eight kinds of prepared traditional Chinese medicine are then additionally added to the plaster, and the plaster of the present invention is formed. The plaster is pasted after a wound surface is cleaned and after drainage, puncture and decompression. The present invention can cure internal diseases from outside and has the functions of clearing away heat and toxic substance, eliminating necrotic tissue and promoting muscles, promoting qi circulation to relieve pain and softening and resolving hard substance. The present invention is particularly suitable for curing bone tuberculosis. Moreover, the present invention also has a good therapeutic effect on non-specificity colitis, mastadenoma, etc.
To provide pure and highly scalable silk protein fragment compositions that may be used across multiple industries for a variety of applications.SOLUTION: A composition includes pure silk fibroin-based protein fragments that are substantially devoid of sericin. The composition has an average weight average molecular weight ranging from about 17 kDa to about 38 kDa. The composition has a polydispersity between about 1.5 and about 3.0. The composition is substantially homogeneous. The composition includes 0 ppm to about 500 ppm of inorganic residues. The composition includes 0 ppm to about 500 ppm of organic residues.SELECTED DRAWING: Figure 79
Disclosed herein are methods of treating, diagnosing, and prognosing GLUT-dependent cancers and OXPHOS-dependent cancers. In some embodiments, the methods comprise administering to a patient in need thereof a GLUT inhibitor and/or an OXPHOS inhibitor. The inhibitors may be administered before, concurrently, or after one another. Suitable GLUT-dependent cancers may include a GLUT4-dependent cancer, a GLUT8-dependent cancer, and a GLUT11-dependent cancer. Suitable GLUT inhibitors may include a GLUT4 inhibitor, a GLUT8 inhibitor, and a GLUT11 inhibitor. Suitable OXPHOS-dependent cancers may include mitochondrial OXPHOS-dependent cancers, including cancers that have developed resistance to treatment with a GLUT-inhibitor.
PROBLEM TO BE SOLVED: To obtain crystal of a methylcarbapenem compound (salt) improved in preservation stability and practically very useful medicines, in particular antimicrobial agent, by crystallizing a methylcarbapenem compound (salt). SOLUTION: This compound is obtained by crystallizing 1-methylcarbapenem compound (salt) shown by the formula. The crystal means a solid whose internal structure is composed of three-dimensionally regularly repeating constituent atoms (units), as distinguished from an amorphous solid having no regular inner structure. The crystal is obtained by, e.g. dissolving the compound (salt) shown by the formula in a solvent (good solvent), and treating the solution by, e.g. enriching as required, mixing with a poor solvent as required and cooling also as required, to make the compound (salt) shown by the formula supersaturated, separate the crystal, and isolate and dry the separated crystal. Separation of the crystal may be started naturally in the reactor, or started or accelerated by adding a seed crystal or stimulation, e.g. by ultrasonic waves.
Vepdegestrant administered as a single dose in Period 1 and Period 2. Carbamazepine administered once a day for 19 days in Period 2.
Neuronal apoptosis is a common pathological change in early brain injury after subarachnoid hemorrhage (SAH), and it is closely associated with neurological deficits. According to previous research, p97 exhibits a remarkable anti-cardiomyocyte apoptosis effect. p97 is a critical molecule in the growth and development of the nervous system. However, it remains unknown whether p97 can exert an anti-neuronal apoptosis effect in SAH. In the present study, we examined the role of p97 in neuronal apoptosis induced after SAH and investigated the underlying mechanism. We established an in vivo SAH mice model and overexpressed the p97 protein through transfection of the mouse cerebral cortex. We analyzed the protective effect of p97 on neurons and evaluated short-term and long-term neurobehavior in mice after SAH. p97 was found to be significantly downregulated in the cerebral cortex of the affected side in mice after SAH. The site showing reduced p97 expression also exhibited a high level of neuronal apoptosis. Adeno-associated virus-mediated overexpression of p97 significantly reduced the extent of neuronal apoptosis, improved early and long-term neurological function, and repaired the neuronal damage in the long term. These neuroprotective effects were accompanied by enhanced proteasome function and inhibition of the integrated stress response (ISR) apoptotic pathway involving eIF2α/CHOP. The administration of the p97 inhibitor NMS-873 induced a contradictory effect. Subsequently, we observed that inhibiting the function of the proteasome with the proteasome inhibitor PS-341 blocked the anti-neuronal apoptosis effect of p97 and enhanced the activation of the ISR apoptotic pathway. However, the detrimental effects of NMS-873 and PS-341 in mice with SAH were mitigated by the administration of the ISR inhibitor ISRIB. These results suggest that p97 can promote neuronal survival and improve neurological function in mice after SAH. The anti-neuronal apoptosis effect of p97 is achieved by enhancing proteasome function and inhibiting the overactivation of the ISR apoptotic pathway.
The present invention pertains to the art of medical technology and discloses a medicine combination and a preparation meod for pregnancy reaction. The raw medicine materials of the medicine combination include seville orange flower, finger citron flower, villous amomum fruit, perilla stem and burnt largehead atractylode. The present invention with functions of clearing liver and stomach, controlling nausea and vomiting and preventing abortion is used for treating naupathia, nausea, vomiting and anorexia in pregnancy. The medicine combination can be made into any acceptable form in clinic or pharmacology, preferably oral form. The property of the raw medicine materials of the medicine combination gives attention to liver, stomach, spleen, lung and kidney, so that the drug property and the functions are more extensive to treat both manifestation and root cause of disease. In addition, the efficacy of the medicine materials has no toxic side effects, thus ensuring the safety of pregnant women.
The invention discloses a traditional Chinese medicinal preparation for anesthesia. Effective components of the traditional Chinese medicinal preparation comprise the following raw materials: keel, spine date seed, albizia bark, Datura stramonium, henbane, caltrop, monkshood, Aconitum kusnezoffii, clove, chinese fevervine herb and root, the root bark of the peony tree, eucommia, natural indigo, common fenugreek seed, honeysuckle flower and bighead atractylodes rhizome. The traditional Chinese medicinal preparation is prepared by compatibility of a plurality of medicinal materials, and has advantages of fast effectiveness, short time of duration, high anaesthesia efficiency, strong controllability during operation and fast revival after operation. After operation, anaesthetic drugs can be timely metabolized and expelled out of the body. The traditional Chinese medicinal preparation has a good curative effect of complications caused by anaesthesia. The traditional Chinese medicinal preparation provided by the invention also has an obvious pain-relieving effect as well as an antishock effect.
Objective.Detection of the epileptogenic zone is critical, especially for patients with drug-resistant epilepsy. Accurately mapping cortical regions exhibiting high activity during spontaneous seizure events while detecting neural activity up to 500 Hz can assist clinicians' surgical decisions and improve patient outcomes.Approach.We designed, fabricated, and tested a novel hybrid, multi-scale micro-electrocorticography (micro-ECoG) array with a unique embedded configuration. This array was compared to a commercially available microelectrode array (Neuronexus) for recording neural activity in rodent sensory cortex elicited by somatosensory evoked potentials and pilocarpine-induced seizures.Main results.Evoked potentials and spatial maps recorded by the multi-scale array ('micros', 'mesos', and 'macros' refering to the relative electrode sizes, 40 micron, 1 mm, and 4 mm respectively) were comparable to the Neuronexus array. The SSEPs recorded with the micros had higher peak amplitudes and greater signal power than those recorded by the larger mesos and macro. Seizure onset events and high-frequency oscillations (∼450 Hz) were detected on the multi-scale, similar to the commercially available array. The micros had greater SNR than the mesos and macro over the 5-1000 Hz frequency range during seizure monitoring. During cortical stimulation experimentation, the mesos successfully elicited motor effects.Significance.Previous studies have compared macro- and microelectrodes for localizing seizure activity in adjacent regions. The multi-scale design validated here is the first to simultaneously measure macro- and microelectrode signals from the same overlapping cortical area. This enables direct comparison of microelectrode recordings to the macroelectrode recordings used in standard neurosurgical practice. Previous studies have also shown that cortical regions generating high-frequency oscillations are at an increased risk for becoming epileptogenic zones. More accurate mapping of these micro seizures may improve surgical outcomes for epilepsy patients.
The primary aim is to recruit hearts from donation which are currently excluded by conventional criteria as aged hearts in patients \> 55 years and ≤ 55 years with multiple risk factors. Secondary aim is to assess outcome in SE-driven transplantation compared to hearts transplanted in the same cardiac surgery centers on the basis of conventional criteria. Tertiary aim is to assess the additional prognostic value of other signs not used for decision-making. These aspects may include diastolic function, preload reserve, coronary microvascular function, and residual innervation of the intrinsic cardiac autonomic system through assessment of HRR in donor heart. In case of donor with age \>55 years o ≤ 55 years but with concomitant ≥ 3 risk factors (diabetes, hypertension, smoking, obesity, hypercholesterolemia) or history of cardiac arrest, the protocol will be applied.
Group B will receive a session of Balance exercises for 30 minutes. Treatment session will be given for 3 days per week for 12 weeks. This balance exercise program consist of three phases:Warm-up phase (5 minutes), after Warm-Up phase, 20 minutes balance exercise training then cooling phase (5 minutes).
This multicenter study describes the population pharmacokinetics (PK) of fluconazole in critically ill patients receiving concomitant extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT) and includes an evaluation of different fluconazole dosing regimens for achievement of target exposure associated with maximal efficacy. Serial blood samples were obtained from critically ill patients on ECMO and CRRT receiving fluconazole. Total fluconazole concentrations were measured in plasma using a validated chromatographic assay. A population PK model was developed and Monte Carlo dosing simulations were performed using Pmetrics in R. The probability of target attainment (PTA) of various dosing regimens to achieve fluconazole area under the curve to minimal inhibitory concentration ratio (AUC0-24/MIC) >100 was estimated. Eight critically ill patients receiving concomitant ECMO and CRRT were included. A two-compartment model including total body weight as a covariate on clearance adequately described the data. The mean (±standard deviation, SD) clearance and volume of distribution were 2.87 ± 0.63 L/h and 15.90 ± 13.29 L, respectively. Dosing simulations showed that current guidelines (initial loading dose of 12 mg/kg then 6 mg/kg q24h) achieved >90% of PTA for a MIC up to 1 mg/L. None of the tested dosing regimens achieved 90% of PTA for MIC above 2 mg/L. Current fluconazole dosing regimen guidelines achieved >90% PTA only for Candida species with MIC <1 mg/L and thus should be only used for Candida-documented infections in critically ill patients receiving concomitant ECMO and CRRT. Total body weight should be considered for fluconazole dose.
One drop of of timolol maleate 0.5% gel is topically applied and massaged into the hemangioma twice per day . This dosage provides an estimated 0.5 mg of timolol per day. The treatment is continued until it is considered to be no longer effective as judged by the physicians.
A system, method, and computer readable medium for measuring limb range of motion. The method includes initializing a scanning area. A classifier trained to recognize limbs is loaded into memory. A frame representing a 3D point cloud having at least one limb of a person in motion is captured. A box fitting algorithm is performed on the captured at least one limb to enable the classifier to identify the at least one limb. One or more boxes generated from the box fitting algorithm are sliced into a plurality of 2D point clouds to measure and record the circumference of each 2D point cloud to obtain limb range of motion parameters. The limb range of motion parameters are a maximum and a minimum size of the at least one limb as a function of soft tissue expansion and contraction of the limb while under pressure, force, and/or motion.
A high performance liquid chromatography method to routinely and reproducibly detect and quantitate metal complexes. The method comprises loading a solution containing metal complexes onto a column, eluting the metal complex from the column with a mobile phase, the mobile phase comprising an excess of a salt of a coordinating anion in a solvent system, and detecting the metal complex with a detector. Eluting the complex from the column with the mobile phase generates a metal complex in which the coordinating anion (which is a competent ligand) out-competes all other potential ligands present for the available coordination sites on the metal. The metal complexes used in the method of the invention can be different metal complexes, or they can be stereoisomers of the same metal complexes. The high performance liquid chromatography method of the present invention is suitable for the separation of diastereomers of the same metal complexes. Also provided is a chiral high performance liquid chromatography method to separate enantiomers of metal complexes. In this chiral high performance liquid chromatography method a chiral column is employed to achieve the separation of the enantiomers of metal complexes.
PURPOSE:To provide the titled odorless and colorless curing water composed of an Ag<+> ion water having specific pH and Ag<+> ion concentration, exhibiting bacteriostatic and bactericidal activity against pathogenic bacteria, effective in disintegrating and absorbing damaged tissue, having excellent rapid activity and harmless to human body. CONSTITUTION:The objective water for curing pathogenic bacterial disease of the skin and external cavity membrane is composed of an Ag<+> ion water having pH of <=5 and an Ag<+> ion concentration of 0.5-10ppm. The restoration and regeneration of the diseased tissue can be promoted by using the curing water at an electrical conductivity of 350-2,000uOMEGA/cm<3> and a dissolved oxygen concentration of 12-30ppm. The concentration of Ag<+> ion in the curing water is a level almost harmless to human body taking the safety value of Ag<+> ion water into account. Since the water has broad antibacterial spectrum, all the participating bacteria are subjected to bacteriostatic or bactericidal effect, the damaged tissue is disintegrated and absorbed and the neoplastic tissue is rapidly generated to cure the disease. The water is useful for the remedy of disease caused by the infection of human skin or external cavity mucosa, etc., with various pathogens such as bacteria.
An increase in systemic inflammation (inflammaging) is one of the hallmarks of aging. Epigenetic (DNA methylation) clocks can quantify the degree of biological aging and this can be reversed by lifestyle and pharmacological intervention. We aimed to investigate whether a multi-component nutritional supplement could reduce systemic inflammation and epigenetic age in healthy older adults.We recruited 80 healthy older participants (mean age ± SD: 71.85 ± 6.23; males = 31, females = 49). Blood and saliva were obtained pre and post a 12-week course of a multi-component supplement, containing: Vitamin B3, Vitamin C, Vitamin D, Omega 3 fish oils, Resveratrol, Olive fruit phenols and Astaxanthin. Plasma GDF-15 and C-reactive protein (CRP) concentrations were quantified as markers of biological aging and inflammation respectively. DNA methylation was assessed in whole blood and saliva and used to derive epigenetic age using various clock algorithms.No difference between the epigenetic and chronological ages of participants was observed pre- and post-treatment by the blood-based Horvath or Hannum clocks, or the saliva-based InflammAge clock. However, in those with epigenetic age acceleration of ≥ 2 years at baseline, a significant reduction in epigenetic age (p = 0.015) and epigenetic age acceleration (p = 0.0058) was observed post-treatment using the saliva-based InflammAge clock. No differences were observed pre- and post-treatment in plasma GDF-15 and CRP, though participants with CRP indicative of an elevated cardiovascular disease risk (hsCRP ≥ 3µg/ml), had a reduction in CRP post-supplementation (p = 0.0195).Our data suggest a possible benefit of combined nutritional supplementation in individuals with an accelerated epigenetic age and inflammaging.
The invention relates to compounds, methods and devices for targeting of optical agents to leukemia affected cells or tissues in a subject. Compounds of the invention include conjugates and bioconjugates comprising a targeting moiety and an optical agent. In an aspect of the invention, the targeting moiety is an amino acid sequence which preferentially binds to leukemia cells. In another aspect of the invention, the optical agent is an imaging agent derived from a pyrazine, azulene, or azaazulene dye. In a further aspect of the invention, the optical agent may comprise a photosensitizer. Some methods of the invention relate to administration, activation, and/or monitoring of compounds of the invention. In an aspect, a compound of the invention is administered to a subject, allowed time to target a leukemia affected cell or tissue in the subject, and the fluorescence intensity of the compound in the subject is measured. Some devices of the invention include means for activation, detection and monitoring of compounds of the invention. In an aspect of the invention, a device includes an electromagnetic radiation source, collector, and detector.
This is an open label, phase I study to determine safety and efficacy of CD34+ cells in the treatment and management of CED and early atherosclerosis. Coronary endothelial function will be assessed in all patients by the administration of intracoronary acetylcholine. Patients with endothelial dysfunction who meet study inclusion criteria will receive granulocyte cell stimulating factor (G-CSF), followed by apheresis. The mobilized peripheral cell product will be processed for selection of CD34+ stem cells, and the purified CD34+ cells will be administered intracoronary during cardiac catheterization. The patients will undergo repeat endothelial function assessment 6 months post-procedure, as well as clinical assessments as described below either via in-person assessment by a nurse or physician, or via phone-call using a standardized questionnaire at 1, 3, and 6 month follow-up visits. At one month, the patient will undergo basic laboratory testing including troponin levels, complete blood count (CBC), electrolyte panel, liver function testing and ECG. At 3 months, the patients will receive a phone follow-up by the study coordinator who will assess the patient for any clinical deterioration or significant worsening in symptoms. At 6 months, the patients will return for a clinical visit, which will include physical examination, basic laboratory testing and follow-up acetylcholine study with angiography to assess for change in endothelial function. The first three patients will be sequentially enrolled, and subsequent enrollment will be held until one month follow-up. Provided there are no safety concerns at this time, enrollment will continue.
BACKGROUND: Cirrhosis comprises a significant health challenge in the Middle East and North African (MENA) region impacting healthcare systems and communities. This study sought to investigate trends in the burden of cirrhosis and other chronic liver disease, different etiologies, deaths, and the disability burden utilizing data from the Global Burden of Disease (GBD) database.
METHODS: Analyzing epidemiological trends from 1990 to 2021 across 21 MENA countries, this research utilized data on age-standardized incidence rates (ASIR), age-standardized death rates, and age-standardized disability-adjusted life years (DALYs) to evaluate the burden of cirrhosis and other chronic liver disease. The study also examined national variations and sociodemographic relationships.
RESULTS: The study identified a 114.9% increase in cirrhosis and other chronic liver disease incidence within the MENA region between 1990 and 2021, with 7,344,030 incident cases reported in 2021. The ASIR showed a steeper rise in females (9.6%) compared to males (7.0%). Etiology-specific analysis revealed an increase in the ASIR for MASLD related cirrhosis and other chronic liver disease by 22.2%, while those due to alcohol as well as hepatitis B and C decreased by 28.1%, 59.3%, and 30%, respectively. Despite the rising incidence, overall age-standardized death rates across all etiologies decreased by 54.3%, with DALYs showing a 51.4% decrease during the same period. Country-specific trends varied significantly, with Oman recording the highest annual ASIR increase (0.64%), and Qatar observing the most substantial annual reduction in age-standardized death rates (-2.88%).
CONCLUSION: The study highlights evolving trends in cirrhosis and other chronic liver disease within the MENA region, emphasizing the necessity for comprehensive, etiology, and gender-specific interventions. Despite an increasing incidence, the observed improvements in mortality rates and age-standardized disability burden indicate progress in public health efforts to mitigate cirrhosis's impact. These findings point to the complex nature of cirrhosis outcomes and the urgent need for tailored strategies to manage its increasing burden effectively.
Participants in the CN condition will not be instructed to use any particular coping strategy to cope with the painful stimulation provided by the Cold Pressor Arm Wrap. Participants in the CN condition will listen to a 20-minute natural history audio recording. The option for this recording is supported by: (a) previous research showing that individuals who were asked to listen to it found it to be a neutral, yet relaxing, passage; (b) the use of this passage as an effective control condition in previous studies.